CRON Cronos Group Inc.

NEUTRAL Impact: 3/10 PRESS-RELEASE
Horizon weeks Filed Jun 16, 2026 Processed 4d 11h ago Wire GlobeNewswire
Press release: activist
Latest settled — T+1d
CRON ▲ +1.50% at T+1d
NEUTRAL call ✓ call won +1.50% · α vs SPY +0.72% · entry $2.67 → $2.71
Next anchor: T+5d in 3d
Last close $2.71 (close Jun 18) · +1.50% from $2.67 entry
Entry anchored
Jun 16, 03:59 PM ET
via Databento tick
T+1d
+1.50%
call +1.50% · α +0.72%
$2.71
settled 4d ago
T+5d
—
call — · α —
—
in 3d
T+20d
—
call — · α —
—
in 24d
T+60d
—
call — · α —
—
in 3mo

Price Chart

Loading chart...

Executive Summary

Cronos Group announced that the TSX accepted its normal course issuer bid (NCIB), allowing repurchases on Canadian exchanges under its existing $50 million share repurchase program. The program, running from May 2026 to May 2027, covers up to 5.02% of outstanding shares and also received an OSC exemption for NASDAQ purchases. This is a routine capital allocation move with no financial results or guidance provided.

Key Financial Metrics

Deal Value
$50.0M

Actionable Insight

The buyback is modest relative to market cap and spread over 11 months, so near-term price impact is likely minimal. Monitor quarterly filings for actual repurchase activity and any changes in cash position.

Key Facts

  • Share repurchase program of up to US$50 million approved by Board on May 8, 2026, commenced May 14, 2026, terminates May 13, 2027.
  • Maximum of 18,712,918 common shares (approximately 5.02% of 373 million outstanding as of June 1, 2026) may be repurchased.
  • TSX NCIB accepted; repurchases on TSX may begin June 19, 2026, limited to 25% of average daily trading volume (53,968 shares/day).
  • Ontario Securities Commission exemption obtained on June 15, 2026, allowing NASDAQ repurchases above Canadian limits.

Financial Impact

Up to $50 million share repurchase, representing ~5% of market cap ($990M).

dilution

Risk Factors

  • Buyback may not be fully executed if management prioritizes other uses of cash.
  • No financial results or guidance provided; fundamentals remain unknown.

Market Snapshot

Exchange
Nasdaq
Sector
Medicinal Chemicals & Botanical Products
Analyst Consensus
89% bullish (9 analysts)

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3313018
4 reports for CRON
Performance horizon
100% Hit rate 3 of 3 directional calls best @ T+20▲ +5.07%Apr 20, 2026
Filters
Rows
Reports for CRON — sortable, filterable
Type Now
Jun 16, 2026
4d ago
Press Release
NEUTRAL ★ 3/10
$2.67 $2.71▲ +1.50%▲ +0.72%$2.71 (+1.50%)
May 11, 2026
5w ago
8-K
BULLISH ★ 7/10
$2.75 $2.77▲ +0.73%▲ +0.86%$2.71 (−1.45%)
Apr 20, 2026
8w ago
Press Release
BEARISH ★ 6/10
$2.76 $2.73▲ +1.09%▲ +0.43%$2.71 (+1.81%)
Feb 26, 2026
16w ago
8-K
BULLISH ★ 8/10
$2.67 $2.67· 0.00%▲ +0.45%$2.71 (+1.50%)
Showing 4 of 4

US Market Status

Market Closed — Opens Mon (29h 37m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access